SeekingAlpha  6 hrs ago  Comment 
ByQuoth the Raven: It was just a couple of months ago that I was lambasted for suggesting that investors might find MannKind's (NASDAQ:MNKD) FDA approval as a good time to short the stock. MannKind bulls didn't seem to think that an FDA approval...
SeekingAlpha  Jul 25  Comment 
By The Behavioral Economist: As an advocate, observer, and proponent of behavioral finance theory, few stocks in recent history have provided me with as fertile a platform for observation and analysis as the Valencia, California-based...
Motley Fool  Jul 24  Comment 
While FDA approval may have come wrapped in a pretty box for shareholders, what is inside the box in terms of FDA warnings could be a huge problem for MannKind and Afrezza.
SeekingAlpha  Jul 23  Comment 
By PharmaGreek: After reading many articles on Seeking Alpha about the assured blockbuster success of AFREZZA, an inhaled ultra-rapid acting insulin for treatment of Type 1 and Type 2 diabetes mellitus from MannKind (NASDAQ:MNKD), I was interested...
Motley Fool  Jul 22  Comment 
These 3 biotechs have lost tons of money every year so far in the 21st century. But could profits be on the horizon?
SeekingAlpha  Jul 21  Comment 
ByPsycho Analyst: My previous article looked at the five largest global Big Pharma companies, ranked by revenues, to see if any of them might be the partner MannKind (NASDAQ:MNKD) needs to market and distribute its just-approved, novel, ultra-fast...
TheStreet.com  Jul 21  Comment 
NEW YORK (TheStreet) -- Today's top swing picks are Cliff Natural Resources , MannKind and PolyOne 1. First, let's look at miner Cliffs Natural Resources.Cliffs traded positively on Friday, closing up 2.19% at $15.84. Friday's range:...
SeekingAlpha  Jul 14  Comment 
ByPsycho Analyst: Now that the FDA has approved MannKind's (NASDAQ:MNKD) inhaled insulin, Afrezza, investors are anxiously awaiting news as to what company, if any, will partner with MNKD to market and distribute this new, potentially blockbusting...
TheStreet.com  Jul 14  Comment 
The Biotech Stock Mailbag has returned after a short summer hiatus. Let's kick off with MannKind .  Tim H. writes: Inevitable Fall of Mannkind. HA HA HA HA HA HA!!!! Shares rocketed after hours on the approval. Where do you come up with your...
Motley Fool  Jul 11  Comment 
MannKind won FDA approval for Afrezza but still faces risks. Is this one the biggest of all?


MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes, cancer, and inflammatory and autoimmune diseases. The company's lead product, the Technosphere Insulin System, meant for the treatment of diabetes, is in a series of pivotal phase III trial in the U.S. This product utilizes MannKind s proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using the company s MedTone inhaler. Besides the company s development of Technosphere, MannKind is pursuing efforts aimed at the discovery and development of novel drugs for metabolic and immunological diseases. The company also has early-stage development programs for the treatment of solid-tumor cancers. MannKind initiated phase I trials with its cancer candidates in early 2007. MannKind's corporate headquarters and immunology research operations are located in Valencia, CA. Significant operations, including the Technosphere Insulin research, development and manufacturing are located in Danbury, CT. The company's initial public offering (IPO) took place in late July 2004.

Business & Financial Metrics[1]

In 2009, MannKind incurred a net loss of $220.1 million and reported no revenue. This represents a 27.4% reduction in net loss from 2008, when the company lost $303.0 million. Since its inception in 1991, MannKind has lost $1.60 billion and generated $3.0 million in revenues.


MannKind's primary competitors include:


  1. MNKD 2009 10-K pg. 64  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki